首页 > 最新文献

Medicinal Chemistry最新文献

英文 中文
Exploring 1-Azaaurones: A Concise Overview of Synthetic Strategies and Biological Activities. 探索1-氮杂龙:合成策略和生物活性的简明概述。
IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-01-01 DOI: 10.2174/0115734064357796250120060204
Naveen Chauhan, Suresh Kumar

Azaaurones are formed by the replacement of intra-cyclic oxygen of the central core of a five-membered furan ring or any other carbon of aurones by a nitrogen atom. However, 1- azaaurone obtained by the replacement of intra-cyclic oxygen is the most prominent and desirable. They are the bioactive compounds acting as potential anti-inflammatory, anticancer, antibacterial, and antiviral agents. They comprise relatively less explored, pharmacologically active compounds exhibiting diverse biological activities that can act as potential lead compounds in the context of drug development. This review represents a comprehensive and updated overview of the synthetic protocols and biological activities of 1-azaaurones and their derivatives, enabling the readers to know about the vast medicinal potential of azaaurones and their derivatives in different areas and prompt the medicinal chemists to emphasize their further exploration. Furthermore, this review also covers some important Structure-Activity Relationships (SAR), highlighting the most potential compounds in each series, providing pivotal scope for further improvisation.

氮aurones是由一个氮原子取代五元呋喃环中心核心的环内氧或任何其他碳的aurones形成的。然而,通过取代环内氧得到的1-氮杂龙是最突出和最理想的。它们是具有生物活性的化合物,具有潜在的抗炎、抗癌、抗菌和抗病毒作用。它们包含相对较少探索的药理学活性化合物,表现出多种生物活性,可以在药物开发的背景下作为潜在的先导化合物。本文综述了1-氮扎aurones及其衍生物的合成方案和生物活性,使读者了解氮扎aurones及其衍生物在不同领域的巨大药用潜力,并促使药物化学家重视其进一步的探索。此外,本综述还涵盖了一些重要的构效关系(SAR),突出了每个系列中最有潜力的化合物,为进一步的即兴创作提供了关键的范围。
{"title":"Exploring 1-Azaaurones: A Concise Overview of Synthetic Strategies and Biological Activities.","authors":"Naveen Chauhan, Suresh Kumar","doi":"10.2174/0115734064357796250120060204","DOIUrl":"10.2174/0115734064357796250120060204","url":null,"abstract":"<p><p>Azaaurones are formed by the replacement of intra-cyclic oxygen of the central core of a five-membered furan ring or any other carbon of aurones by a nitrogen atom. However, 1- azaaurone obtained by the replacement of intra-cyclic oxygen is the most prominent and desirable. They are the bioactive compounds acting as potential anti-inflammatory, anticancer, antibacterial, and antiviral agents. They comprise relatively less explored, pharmacologically active compounds exhibiting diverse biological activities that can act as potential lead compounds in the context of drug development. This review represents a comprehensive and updated overview of the synthetic protocols and biological activities of 1-azaaurones and their derivatives, enabling the readers to know about the vast medicinal potential of azaaurones and their derivatives in different areas and prompt the medicinal chemists to emphasize their further exploration. Furthermore, this review also covers some important Structure-Activity Relationships (SAR), highlighting the most potential compounds in each series, providing pivotal scope for further improvisation.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":"843-857"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143033450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Step Towards Development and Bio-evaluation of a Novel Radio-ligand 99mTc-CYX-DTPA Targeting Sigma 2 Receptors. 靶向Sigma 2受体的新型放射配体99mTc-CYX-DTPA的研制与生物评价
IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-01-01 DOI: 10.2174/0115734064329861250122113332
Ritika Chaudhary, Shubhra Chaturvedi, Divya Gautam, Vishakha Chaudhary, Deepika Sharma, Presenjit, Aastha Garg, Madhu Chopra, Anil Kumar Mishra

Introduction: Development of theranostics agents targeted towards particular receptors can effectively help in the management of cancer. The overexpression of the sigma-2 receptor (S2R) in tumors establishes it as a prominent biomarker for cancer cells.

Methods: Radiotheranostics rely on the design of specific molecules having versatility in applications of diagnosis and therapy by merely changing the radioisotope. We have designed a novel radiotheranostic S2R-targeted ligand using cyclohexylpiperazine and performed docking studies to narrow down the potential efficacious ligand. The potential molecule with G-score = -7.0 kcal/mol, was then synthesized using a three steps reaction including conjugation of 2-(4- cyclohexylpiperazine-1-yl)ethyl(CYX) with DTPA chelator. Subsequently, the molecule has been radiolabelled with 99mTc using stannous chloride as a reducing agent, and a radiolabellieng efficiency of 95.0 ± 0.59% for 99mTc-CYX-DTPA. As proof of concept, the molecule has been evaluated for its binding affinity and specificity using sigma receptors isolated from the liver membrane homogenates of mice. The binding affinity was found to be Kd = 12.84 ± 0.395 nM; Bmax = 0.5258 ± 0.001 fmol/mg, indicating a high affinity for the receptors.

Results: In addition, the molecule was also assessed for biocompatibility using haemolysis analysis and cytotoxicity on HEK cells and MDA-MB-23, wherein the molecule showed no significant cytotoxicity up to 72 h on HEK cells and 32.42% cytotoxicity on MDA-MB-231 cells.

Conclusion: The future work will concentrate on the demonstration of in vivo targeting and sitespecific accumulation of the molecule along with its suitability for theranostics applications.

导读:针对特定受体的治疗药物的开发可以有效地帮助癌症的管理。肿瘤中sigma-2受体(S2R)的过表达使其成为癌细胞的重要生物标志物。方法:放射治疗依赖于特定分子的设计,通过改变放射性同位素在诊断和治疗中的应用具有通用性。我们使用环己基哌嗪设计了一种新的放射治疗s2r靶向配体,并进行对接研究以缩小潜在有效配体的范围。然后用2-(4-环己基哌嗪-1-基)乙基(CYX)与DTPA螯合剂偶联三步反应合成了G-score = -7.0 kcal/mol的势分子。随后,用氯化亚锡作为还原剂用99mTc对该分子进行放射性标记,99mTc- cyx - dtpa的放射性标记效率为95.0±0.59%。作为概念的证明,该分子已经通过从小鼠肝膜匀浆中分离的sigma受体来评估其结合亲和力和特异性。结合亲和力Kd = 12.84±0.395 nM;Bmax = 0.5258±0.001 fmol/mg,对受体有较高亲和力。结果:此外,还通过溶血分析和对HEK细胞和MDA-MB-23的细胞毒性评估了该分子的生物相容性,其中该分子对HEK细胞的细胞毒性长达72 h,对MDA-MB-231细胞的细胞毒性为32.42%。结论:未来的工作将集中在证明分子的体内靶向性和位点特异性积累以及其治疗应用的适用性上。
{"title":"A Step Towards Development and Bio-evaluation of a Novel Radio-ligand <sup>99m</sup>Tc-CYX-DTPA Targeting Sigma 2 Receptors.","authors":"Ritika Chaudhary, Shubhra Chaturvedi, Divya Gautam, Vishakha Chaudhary, Deepika Sharma, Presenjit, Aastha Garg, Madhu Chopra, Anil Kumar Mishra","doi":"10.2174/0115734064329861250122113332","DOIUrl":"https://doi.org/10.2174/0115734064329861250122113332","url":null,"abstract":"<p><strong>Introduction: </strong>Development of theranostics agents targeted towards particular receptors can effectively help in the management of cancer. The overexpression of the sigma-2 receptor (S2R) in tumors establishes it as a prominent biomarker for cancer cells.</p><p><strong>Methods: </strong>Radiotheranostics rely on the design of specific molecules having versatility in applications of diagnosis and therapy by merely changing the radioisotope. We have designed a novel radiotheranostic S2R-targeted ligand using cyclohexylpiperazine and performed docking studies to narrow down the potential efficacious ligand. The potential molecule with G-score = -7.0 kcal/mol, was then synthesized using a three steps reaction including conjugation of 2-(4- cyclohexylpiperazine-1-yl)ethyl(CYX) with DTPA chelator. Subsequently, the molecule has been radiolabelled with <sup>99m</sup>Tc using stannous chloride as a reducing agent, and a radiolabellieng efficiency of 95.0 ± 0.59% for <sup>99m</sup>Tc-CYX-DTPA. As proof of concept, the molecule has been evaluated for its binding affinity and specificity using sigma receptors isolated from the liver membrane homogenates of mice. The binding affinity was found to be K<sub>d</sub> = 12.84 ± 0.395 nM; B<sub>max</sub> = 0.5258 ± 0.001 fmol/mg, indicating a high affinity for the receptors.</p><p><strong>Results: </strong>In addition, the molecule was also assessed for biocompatibility using haemolysis analysis and cytotoxicity on HEK cells and MDA-MB-23, wherein the molecule showed no significant cytotoxicity up to 72 h on HEK cells and 32.42% cytotoxicity on MDA-MB-231 cells.</p><p><strong>Conclusion: </strong>The future work will concentrate on the demonstration of <i>in vivo</i> targeting and sitespecific accumulation of the molecule along with its suitability for theranostics applications.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":"21 6","pages":"582-593"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
De novo Drug Design and Repurposing to Suppress Liver Cancer via VEGF-R1 Mechanism: Comprehensive Molecular Docking, Molecular Dynamics Simulations and ADME Estimation. 通过VEGF-R1机制抑制肝癌的新药物设计和再利用:综合分子对接,分子动力学模拟和ADME估计。
IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-01-01 DOI: 10.2174/0115734064333811240928105309
Soykan Agar
<p><strong>Aim: </strong>The aim is to halt the progression of liver cancer (Hepatocellular carcinoma) by suppressing the VEGF-R1 receptor using Myricetin and its <i>de novo</i>-designed analogues.</p><p><strong>Background: </strong>VEGF/VEGFR autocrine signalling promotes the growth, progression, and metastasis of Hepatocellular carcinoma, making the development of molecularly targeted therapies highly feasible. Invasive and metastatic behaviours in various cancers, including hepatocellular carcinoma (HCC), are closely monitored through the use of VEGF signalling pathway inhibitors. Specifically in HCC, VEGFR-1 facilitates the invasive capabilities of cancer cells primarily by triggering the epithelial-mesenchymal transition (EMT) process. VEGFR-1 significantly influences the activity of proteolytic enzymes that are critical for the invasive behaviour of HCC cells. Notably, a novel mechanism has been discovered where VEGFR-1 activation leads to the upregulation of MMP-9, thereby enhancing the invasiveness of HCC cells. The scientists, in their study, have elaborated on the various antiangiogenic agents developed for the treatment of HCC. They have highlighted clinical trials that explore the efficacy of these treatments, which include the application of monoclonal antibodies and small-molecule kinase inhibitors designed to target specific pathways involved in tumour angiogenesis and growth.</p><p><strong>Objective: </strong>Creating a pharmaceutical chemistry table regarding "Structure-Activity Relationship of New Compounds on anticancer''. To do so, Myricetin and its <i>de novo</i> designed structured variants were used in molecular docking, molecular dynamics, cluster analyses, and 1H NMR estimation to specifically understand and enhance the mechanism of suppressing the VEGF-R1 receptor.</p><p><strong>Methods: </strong>Proper ligands (Myricetin and its analogues) and receptor (VEGF-R1) preparations, and optimizations were done using the density functional theory (DFT)/B3LYP function along with the 6-31G(d,p) basis set principle in the latest software programs such as Gaussian 09, Gauss View 6.0 and Avogadro. Then using PyRx and Autodock Vina 1.1.2., many molecular docking trials were achieved with 100 posed simulations in each run. An extensive cluster analysis was performed to identify the most optimal docking poses with the highest accumulation and most favourable binding interactions, ensuring the accuracy of the study. The docking configurations that exhibited the most precise and accurate poses with lowest inhibition constants were chosen as initial structured data for subsequent Molecular Dynamics (MD) simulations for each drug candidate. To verify the molecular docking results, MD runs were achieved in our supercomputers and the trajectory analyses were made. The data confirmed what was found in molecular docking results, verifying the high efficiency of the druggable molecules' inhibition towards VEGF-R1.</p><p><strong>Results: </stron
目的:目的是通过使用杨梅素及其新设计的类似物抑制VEGF-R1受体来阻止肝癌(肝细胞癌)的进展。背景:VEGF/VEGFR自分泌信号可促进肝细胞癌的生长、进展和转移,这使得开发分子靶向治疗变得非常可行。通过使用VEGF信号通路抑制剂,可以密切监测包括肝细胞癌(HCC)在内的各种癌症的侵袭性和转移性行为。特别是在HCC中,VEGFR-1主要通过触发上皮-间质转化(EMT)过程来促进癌细胞的侵袭能力。VEGFR-1显著影响对HCC细胞侵袭行为至关重要的蛋白水解酶的活性。值得注意的是,已经发现了一种新的机制,即VEGFR-1激活导致MMP-9的上调,从而增强HCC细胞的侵袭性。在他们的研究中,科学家们详细阐述了用于治疗HCC的各种抗血管生成药物。他们强调了探索这些治疗效果的临床试验,其中包括单克隆抗体和小分子激酶抑制剂的应用,这些抑制剂设计用于肿瘤血管生成和生长的特定途径。目的:编制“抗癌新化合物构效关系”药物化学表。为此,我们利用杨梅素及其从头设计的结构变体进行分子对接、分子动力学、聚类分析和1H NMR估计,专门了解和增强抑制VEGF-R1受体的机制。方法:选用合适的配体(杨梅素及其类似物)和受体(VEGF-R1)制备,利用密度泛函理论(DFT)/B3LYP函数和6-31G(d,p)基集原理,在最新的Gaussian 09、Gauss View 6.0和Avogadro软件中进行优化。然后使用PyRx和Autodock Vina 1.1.2。在美国,许多分子对接试验在每次运行中进行了100次模拟。进行了广泛的聚类分析,以确定具有最高积累和最有利的结合相互作用的最优对接姿势,确保研究的准确性。选择具有最低抑制常数的最精确位姿的对接构型作为初始结构化数据,用于后续每种候选药物的分子动力学(MD)模拟。为了验证分子对接的结果,在我们的超级计算机上进行了MD运行,并进行了轨迹分析。该数据证实了分子对接结果的发现,验证了可药物分子对VEGF-R1的高效抑制。结果:与原始杨梅素(-4.77 kcal/mol)相比,胺衍生杨梅素具有较高的对接分数(-10.56 kcal/mol)和较高的抑制常数,而氟衍生杨梅素(-6.45 kcal/mol)在前两个分子之间对VEGF-R1具有亲和力。因此,研究了所有分子在药物化学方面的构效关系,使我们对杨梅素的有机结构对抑制肝癌进展的作用有了更深入的了解。此外,ADME研究表明,胺和氟化衍生杨梅素分子都是很好的候选药物。结论:通过对杨梅素进行特定官能团修饰,杨梅素具有潜在的抗癌潜力。通过全面的计算机计算分析,我们的研究小组通过胺和氟衍生杨梅素的羟基来增强杨梅素的抑制能力,从而提高对接分数和抑制常数。分子对接和MD模拟的研究结果为这些分子作为潜在药物在癌症研究中的体外和体内研究提供了有希望的基础。
{"title":"<i>De novo</i> Drug Design and Repurposing to Suppress Liver Cancer <i>via</i> VEGF-R1 Mechanism: Comprehensive Molecular Docking, Molecular Dynamics Simulations and ADME Estimation.","authors":"Soykan Agar","doi":"10.2174/0115734064333811240928105309","DOIUrl":"https://doi.org/10.2174/0115734064333811240928105309","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Aim: &lt;/strong&gt;The aim is to halt the progression of liver cancer (Hepatocellular carcinoma) by suppressing the VEGF-R1 receptor using Myricetin and its &lt;i&gt;de novo&lt;/i&gt;-designed analogues.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;VEGF/VEGFR autocrine signalling promotes the growth, progression, and metastasis of Hepatocellular carcinoma, making the development of molecularly targeted therapies highly feasible. Invasive and metastatic behaviours in various cancers, including hepatocellular carcinoma (HCC), are closely monitored through the use of VEGF signalling pathway inhibitors. Specifically in HCC, VEGFR-1 facilitates the invasive capabilities of cancer cells primarily by triggering the epithelial-mesenchymal transition (EMT) process. VEGFR-1 significantly influences the activity of proteolytic enzymes that are critical for the invasive behaviour of HCC cells. Notably, a novel mechanism has been discovered where VEGFR-1 activation leads to the upregulation of MMP-9, thereby enhancing the invasiveness of HCC cells. The scientists, in their study, have elaborated on the various antiangiogenic agents developed for the treatment of HCC. They have highlighted clinical trials that explore the efficacy of these treatments, which include the application of monoclonal antibodies and small-molecule kinase inhibitors designed to target specific pathways involved in tumour angiogenesis and growth.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;Creating a pharmaceutical chemistry table regarding \"Structure-Activity Relationship of New Compounds on anticancer''. To do so, Myricetin and its &lt;i&gt;de novo&lt;/i&gt; designed structured variants were used in molecular docking, molecular dynamics, cluster analyses, and 1H NMR estimation to specifically understand and enhance the mechanism of suppressing the VEGF-R1 receptor.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Proper ligands (Myricetin and its analogues) and receptor (VEGF-R1) preparations, and optimizations were done using the density functional theory (DFT)/B3LYP function along with the 6-31G(d,p) basis set principle in the latest software programs such as Gaussian 09, Gauss View 6.0 and Avogadro. Then using PyRx and Autodock Vina 1.1.2., many molecular docking trials were achieved with 100 posed simulations in each run. An extensive cluster analysis was performed to identify the most optimal docking poses with the highest accumulation and most favourable binding interactions, ensuring the accuracy of the study. The docking configurations that exhibited the most precise and accurate poses with lowest inhibition constants were chosen as initial structured data for subsequent Molecular Dynamics (MD) simulations for each drug candidate. To verify the molecular docking results, MD runs were achieved in our supercomputers and the trajectory analyses were made. The data confirmed what was found in molecular docking results, verifying the high efficiency of the druggable molecules' inhibition towards VEGF-R1.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/stron","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":"21 6","pages":"501-515"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent Advances in the Medicinal Chemistry of Cancer (Part II). 肿瘤药物化学的最新进展(第二部分)。
IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-01-01 DOI: 10.2174/0115734064428200250716113612
Isıl Yıldırım
{"title":"Recent Advances in the Medicinal Chemistry of Cancer (Part II).","authors":"Isıl Yıldırım","doi":"10.2174/0115734064428200250716113612","DOIUrl":"10.2174/0115734064428200250716113612","url":null,"abstract":"","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":"595-596"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144682748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Isoindoline-1,3-dione Derivatives as Prototypes for Anticonvulsant Drug Discovery. 异吲哚-1,3-二酮衍生物作为抗惊厥药物发现的原型。
IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-01-01 DOI: 10.2174/0115734064336758241113180402
Rafael Consolin Chelucci, Richard Chiquetto, Diego Eidy Chiba, Cauê Benito Scarim, Chung Man Chin, Jean Leandro Dos Santos

Introduction: Epilepsy encompasses numerous syndromes characterized by spontaneous, intermittent, and abnormal electrical activity in the brain. Affecting about 1-2% of the population, it is estimated that approximately 30-40% of patients experience refractory epilepsy, which does not respond to traditional anticonvulsant drugs.

Methods: Therefore, developing novel, safe, and effective antiepileptic drugs remains a medical need. In this study, we synthesized a series of isoindoline-1,3-dione derivatives and evaluated their anticonvulsant effects.

Results: Compounds (2a-j) and (5) were obtained with yields ranging from 52-97%. These compounds were assessed for their protective effects on the following parameters: a) time to first seizure (seizure latency), b) seizure duration, and c) mortality rate post-seizure. The most active compound, (2a), increased seizure latency, reduced seizure duration, and lowered the mortality rate.

Conclusion: These findings indicate that compound (2a) is a promising new anticonvulsant prototype, offering an alternative to current anticonvulsant drugs.

简介:癫痫包括许多以自发性、间歇性和异常脑电活动为特征的综合征。该病影响约1-2%的人口,估计约有30-40%的患者患有难治性癫痫,这对传统抗惊厥药物无反应。目的:因此,开发新型、安全、有效的抗癫痫药物仍然是一种医学需求。本研究合成了一系列异吲哚-1,3-二酮衍生物,并评价了它们的抗惊厥作用。结果:得到化合物(2a-j)和(5),收率在52% ~ 97%之间。评估这些化合物对以下参数的保护作用:a)首次发作时间(发作潜伏期),b)发作持续时间,c)发作后死亡率。最有效的化合物(2a)增加了癫痫发作潜伏期,缩短了癫痫发作持续时间,降低了死亡率。结论:化合物(2a)是一种很有前景的新型抗惊厥药物原型,为现有的抗惊厥药物提供了一种替代方案。
{"title":"Isoindoline-1,3-dione Derivatives as Prototypes for Anticonvulsant Drug Discovery.","authors":"Rafael Consolin Chelucci, Richard Chiquetto, Diego Eidy Chiba, Cauê Benito Scarim, Chung Man Chin, Jean Leandro Dos Santos","doi":"10.2174/0115734064336758241113180402","DOIUrl":"10.2174/0115734064336758241113180402","url":null,"abstract":"<p><strong>Introduction: </strong>Epilepsy encompasses numerous syndromes characterized by spontaneous, intermittent, and abnormal electrical activity in the brain. Affecting about 1-2% of the population, it is estimated that approximately 30-40% of patients experience refractory epilepsy, which does not respond to traditional anticonvulsant drugs.</p><p><strong>Methods: </strong>Therefore, developing novel, safe, and effective antiepileptic drugs remains a medical need. In this study, we synthesized a series of isoindoline-1,3-dione derivatives and evaluated their anticonvulsant effects.</p><p><strong>Results: </strong>Compounds (2a-j) and (5) were obtained with yields ranging from 52-97%. These compounds were assessed for their protective effects on the following parameters: a) time to first seizure (seizure latency), b) seizure duration, and c) mortality rate post-seizure. The most active compound, (2a), increased seizure latency, reduced seizure duration, and lowered the mortality rate.</p><p><strong>Conclusion: </strong>These findings indicate that compound (2a) is a promising new anticonvulsant prototype, offering an alternative to current anticonvulsant drugs.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":" ","pages":"1000-1007"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142979072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
One-Pot Synthesis of Benzoxazoles: A Promising Approach to Aromatic Heterocyclic Compounds Preparation. 一锅法合成苯并恶唑:一种制备芳香族杂环化合物的新方法。
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-01-01 DOI: 10.2174/0115734064326002240912102121
Monika Chauhan, Sumitra Nain

Considering the necessity for broad synthetic operations, integrating various reactions into a single pot operation is an intriguing approach to improve synthetic efficiency. One-pot operations may serve as an effective way to minimize the amount of chemical waste generated, save time, avoid multiple purification processes, accomplish numerous transformations, and make multiple bonds in one pot. Therefore, "pot economy" should be considered while designing a synthesis process, since a one-pot reaction can be effective and environmentally safe. Outstanding synthesis has rapidly increased over the last ten years. This study's main goal was to illustrate various one-pot methods that lead to advantageous synthesis.

考虑到广泛合成操作的必要性,将各种反应整合到一个单一的锅操作中是提高合成效率的一个有趣的方法。一锅法可以最大限度地减少化学废物的产生,节省时间,避免多次净化过程,完成多次转化,在一锅中形成多个键。因此,在设计合成工艺时应考虑“锅经济”,因为一锅反应既有效又环保。杰出的合成在过去十年中迅速增加。本研究的主要目的是说明各种一锅法,导致有利的合成。
{"title":"One-Pot Synthesis of Benzoxazoles: A Promising Approach to Aromatic Heterocyclic Compounds Preparation.","authors":"Monika Chauhan, Sumitra Nain","doi":"10.2174/0115734064326002240912102121","DOIUrl":"10.2174/0115734064326002240912102121","url":null,"abstract":"<p><p>Considering the necessity for broad synthetic operations, integrating various reactions into a single pot operation is an intriguing approach to improve synthetic efficiency. One-pot operations may serve as an effective way to minimize the amount of chemical waste generated, save time, avoid multiple purification processes, accomplish numerous transformations, and make multiple bonds in one pot. Therefore, \"pot economy\" should be considered while designing a synthesis process, since a one-pot reaction can be effective and environmentally safe. Outstanding synthesis has rapidly increased over the last ten years. This study's main goal was to illustrate various one-pot methods that lead to advantageous synthesis.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":"21 4","pages":"251-263"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Design and Synthesis of 3-(Phenylsulfonamido)benzamide Derivatives as Potent Carbonic Anhydrase IX Inhibitors: Biological Evaluations and Molecular Modeling Studies. 作为碳酸酐酶IX抑制剂的3-(苯磺胺)苯酰胺衍生物的设计和合成:生物学评价和分子模拟研究。
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-01-01 DOI: 10.2174/0115734064325144240823073504
Mohammad A Khanfar, Mohammad Saleh

Introduction: Carbonic anhydrase IX (CAIX) is known to be overexpressed in various tumors and plays a significant role in tumor development and progression.

Methods: A series of 3-(benzylsulfonamido)benzamides derivatives was synthesized and tested for their CAIX inhibitory activities. The two most active compounds were subjected to cytotoxicity testing against a panel of 60 cancer cell lines.

Results: Many of the synthesized compounds successfully inhibited CAIX activities, exhibiting IC50 values in the low nanomolar range. The most potent CAIX inhibitor was compound 14, with an IC50 of 140 nM. Structure-activity relationship analysis of the synthesized compounds supported with molecular docking revealed strong coordination of sulfonamide moiety with the catalytic Zn2+ metal, hydrophobic interactions of the benzylsulfonamido ring with a hydrophobic pocket, and π- stacking interactions of the aryl ring with an aromatic surface. The two most active analogues (10 and 14) were further tested for their antiproliferative activities in the NCI-60 human tumor cell lines. Notably, compound 14 demonstrated potent growth inhibitory effects against several cancer cell lines.

Conclusion: The synthesized analogues represent a novel scaffold for the treatment of different types of cancer by targeting CAIX.

碳酸酐酶IX (carbon anhydrase IX, CAIX)已知在多种肿瘤中过表达,在肿瘤的发生发展中起重要作用。方法:合成一系列3-(苄基磺胺)苯酰胺衍生物,并对其CAIX抑制活性进行测定。两种最有效的化合物对60种癌细胞进行了细胞毒性测试。结果:许多合成的化合物成功地抑制了CAIX活性,IC50值在低纳摩尔范围内。最有效的CAIX抑制剂是化合物14,IC50为140 nM。通过分子对接对合成的化合物进行构效关系分析,发现磺酰胺部分与催化Zn2+金属具有较强的配位性,苯基磺酰胺环与疏水袋具有疏水相互作用,芳基环与芳表面具有π-堆叠相互作用。两种最活跃的类似物(10和14)在NCI-60人肿瘤细胞系中进一步测试了它们的抗增殖活性。值得注意的是,化合物14显示出对几种癌细胞系的有效生长抑制作用。结论:合成的类似物是一种靶向CAIX治疗不同类型癌症的新型支架。
{"title":"Design and Synthesis of 3-(Phenylsulfonamido)benzamide Derivatives as Potent Carbonic Anhydrase IX Inhibitors: Biological Evaluations and Molecular Modeling Studies.","authors":"Mohammad A Khanfar, Mohammad Saleh","doi":"10.2174/0115734064325144240823073504","DOIUrl":"10.2174/0115734064325144240823073504","url":null,"abstract":"<p><strong>Introduction: </strong>Carbonic anhydrase IX (CAIX) is known to be overexpressed in various tumors and plays a significant role in tumor development and progression.</p><p><strong>Methods: </strong>A series of 3-(benzylsulfonamido)benzamides derivatives was synthesized and tested for their CAIX inhibitory activities. The two most active compounds were subjected to cytotoxicity testing against a panel of 60 cancer cell lines.</p><p><strong>Results: </strong>Many of the synthesized compounds successfully inhibited CAIX activities, exhibiting IC<sub>50</sub> values in the low nanomolar range. The most potent CAIX inhibitor was compound 14, with an IC<sub>50</sub> of 140 nM. Structure-activity relationship analysis of the synthesized compounds supported with molecular docking revealed strong coordination of sulfonamide moiety with the catalytic Zn<sup>2+</sup> metal, hydrophobic interactions of the benzylsulfonamido ring with a hydrophobic pocket, and π- stacking interactions of the aryl ring with an aromatic surface. The two most active analogues (10 and 14) were further tested for their antiproliferative activities in the NCI-60 human tumor cell lines. Notably, compound 14 demonstrated potent growth inhibitory effects against several cancer cell lines.</p><p><strong>Conclusion: </strong>The synthesized analogues represent a novel scaffold for the treatment of different types of cancer by targeting CAIX.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":"21 2","pages":"160-167"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143502269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In silico Study of Novel Tryptanthrin-Based Topoisomerase Inhibitors. 新型色氨酸基拓扑异构酶抑制剂的计算机研究。
IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-01-01 DOI: 10.2174/0115734064334604241014024205
Mukesh Kumar Kumawat, Kapil Kumar

Background: Over the past ten years, a remarkable number of changes have occurred in the field of cancer drug research. Most anticancer drugs from the first generation work by breaking down DNA, preventing its production, interfering with cell division processes, or attaching to microtubules. The potential use of tryptanthrin as well as its analogues is well documented for anticancer properties.

Objective: To design a novel hybrid of tryptanthrin analogs with expected anticancer activity.

Methods: By changing the C-6 carbonyl position of the tryptanthrin molecule, a set of 72 derivatives of substituted-6-benzylidine-6H-indolo[2,1-b] quinazoline-12-one was developed. These ligands were screened in silico using Schrodinger Glide extra precision docking against DNA topoisomerase using doxorubicin and teniposide as references to identify their potential anticancer properties. Further, these ligands were subjected to an in silico ADMET study to identify their drug likeliness.

Results: Combined results of molecular docking and in silico ADMET study suggest that out of the total 72 ligands, 6 ligands RC 51, RC 29, RC 42, RC 3, RC 54, and RC 63 were showing very better binding affinity than the natural ligand adenylyl-imidodiphosphate and the two standard reference drugs- doxorubicin and teniposide.

Conclusion: Our computational approach was successful in identifying ligands that are potentially potent topoisomerase inhibitors. These can be tested further using in vitro and in vivo analysis.

背景:在过去的十年中,癌症药物研究领域发生了显著的变化。从第一代开始,大多数抗癌药物都是通过分解DNA、阻止其产生、干扰细胞分裂过程或附着在微管上起作用的。色氨酸及其类似物的潜在用途已被充分证明具有抗癌特性。目的:设计一种具有抗癌活性的新型杂化色氨酸类似物。方法:通过改变色氨酸分子的C-6羰基位置,合成了取代-6-苄基- 6h -吲哚[2,1-b]喹唑啉-12- 1的72个衍生物。这些配体使用Schrodinger Glide超精密对接DNA拓扑异构酶,以阿霉素和替尼泊苷为参考,在硅上筛选,以确定其潜在的抗癌特性。此外,对这些配体进行了计算机ADMET研究,以确定它们的药物可能性。结果:结合分子对接和硅ADMET研究结果表明,在72个配体中,RC 51、RC 29、RC 42、RC 3、RC 54和RC 63 6个配体的结合亲和力比天然配体腺苷酰亚胺二磷酸和两种标准参比药物阿霉素和替尼泊苷表现出非常好的结合亲和力。结论:我们的计算方法成功地鉴定了潜在的强效拓扑异构酶抑制剂配体。这些可以进一步使用体外和体内分析进行测试。
{"title":"<i>In silico</i> Study of Novel Tryptanthrin-Based Topoisomerase Inhibitors.","authors":"Mukesh Kumar Kumawat, Kapil Kumar","doi":"10.2174/0115734064334604241014024205","DOIUrl":"https://doi.org/10.2174/0115734064334604241014024205","url":null,"abstract":"<p><strong>Background: </strong>Over the past ten years, a remarkable number of changes have occurred in the field of cancer drug research. Most anticancer drugs from the first generation work by breaking down DNA, preventing its production, interfering with cell division processes, or attaching to microtubules. The potential use of tryptanthrin as well as its analogues is well documented for anticancer properties.</p><p><strong>Objective: </strong>To design a novel hybrid of tryptanthrin analogs with expected anticancer activity.</p><p><strong>Methods: </strong>By changing the C-6 carbonyl position of the tryptanthrin molecule, a set of 72 derivatives of substituted-6-benzylidine-6H-indolo[2,1-b] quinazoline-12-one was developed. These ligands were screened <i>in silico</i> using Schrodinger Glide extra precision docking against DNA topoisomerase using doxorubicin and teniposide as references to identify their potential anticancer properties. Further, these ligands were subjected to an <i>in silico</i> ADMET study to identify their drug likeliness.</p><p><strong>Results: </strong>Combined results of molecular docking and <i>in silico</i> ADMET study suggest that out of the total 72 ligands, 6 ligands RC 51, RC 29, RC 42, RC 3, RC 54, and RC 63 were showing very better binding affinity than the natural ligand adenylyl-imidodiphosphate and the two standard reference drugs- doxorubicin and teniposide.</p><p><strong>Conclusion: </strong>Our computational approach was successful in identifying ligands that are potentially potent topoisomerase inhibitors. These can be tested further using <i>in vitro</i> and <i>in vivo</i> analysis.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":"21 6","pages":"516-535"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Arylcarboxamide Derivatives as Promising HDAC8 Inhibitors: An Overview in Light of Structure-activity Relationship and Binding Mode of Interaction Analysis. 芳基羧胺衍生物作为有前景的HDAC8抑制剂:基于构效关系和相互作用结合模式分析的综述
IF 2.6 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-01-01 DOI: 10.2174/0115734064329669241007060848
Suvankar Banerjee, Sandip Kumar Baidya, Tarun Jha, Balaram Ghosh, Nilanjan Adhikari

HDAC8 is associated with several disease conditions as well as various cancers of several organs and hematological malignancies. To counter such pathophysiological and disease conditions, inhibition of HDAC8 may be a promising approach for anticancer drug development. In this article, a detail of arylcarboxamide-based potential HDAC8 inhibitors has been outlined. Considering their binding pattern of interactions along with the chemical features, effective and selective novel HDAC8 inhibitors can be designed further. Therefore, modification of these compounds provides greater possibilities for the development of novel HDAC8 inhibitors. Nevertheless, structural modification of such arylcarboxamide derivatives may be able to produce potent dual-inhibitory compounds along with HDAC8 inhibition. Thus, this article is quite useful for exploring and identifying several possibilities for arylcarboxamide-based HDAC8 inhibitors. Moreover, it can be concluded that further study of the arylcarboxamide-based HDAC8 inhibitors can be effectively used for the treatment of different cancerous and non-cancerous diseases.

HDAC8与几种疾病以及几种器官的各种癌症和血液恶性肿瘤有关。为了对抗这种病理生理和疾病状况,抑制HDAC8可能是一种很有前途的抗癌药物开发方法。在这篇文章中,详细介绍了芳基羧胺类潜在的HDAC8抑制剂。考虑到它们相互作用的结合模式和化学特性,可以进一步设计有效和选择性的新型HDAC8抑制剂。因此,这些化合物的修饰为开发新型HDAC8抑制剂提供了更大的可能性。然而,这种芳基羧酰胺衍生物的结构修饰可能能够产生有效的双抑制化合物,同时抑制HDAC8。因此,本文对于探索和确定几种基于芳基羧胺的HDAC8抑制剂的可能性非常有用。进一步研究芳基甲酰胺类HDAC8抑制剂可有效用于不同癌性和非癌性疾病的治疗。
{"title":"Arylcarboxamide Derivatives as Promising HDAC8 Inhibitors: An Overview in Light of Structure-activity Relationship and Binding Mode of Interaction Analysis.","authors":"Suvankar Banerjee, Sandip Kumar Baidya, Tarun Jha, Balaram Ghosh, Nilanjan Adhikari","doi":"10.2174/0115734064329669241007060848","DOIUrl":"https://doi.org/10.2174/0115734064329669241007060848","url":null,"abstract":"<p><p>HDAC8 is associated with several disease conditions as well as various cancers of several organs and hematological malignancies. To counter such pathophysiological and disease conditions, inhibition of HDAC8 may be a promising approach for anticancer drug development. In this article, a detail of arylcarboxamide-based potential HDAC8 inhibitors has been outlined. Considering their binding pattern of interactions along with the chemical features, effective and selective novel HDAC8 inhibitors can be designed further. Therefore, modification of these compounds provides greater possibilities for the development of novel HDAC8 inhibitors. Nevertheless, structural modification of such arylcarboxamide derivatives may be able to produce potent dual-inhibitory compounds along with HDAC8 inhibition. Thus, this article is quite useful for exploring and identifying several possibilities for arylcarboxamide-based HDAC8 inhibitors. Moreover, it can be concluded that further study of the arylcarboxamide-based HDAC8 inhibitors can be effectively used for the treatment of different cancerous and non-cancerous diseases.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":"21 6","pages":"471-500"},"PeriodicalIF":2.6,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145149517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring Quinoline Derivatives: Their Antimalarial Efficacy and Structural Features. 喹啉衍生物的抗疟功效及结构特征研究。
IF 1.9 4区 医学 Q3 CHEMISTRY, MEDICINAL Pub Date : 2025-01-01 DOI: 10.2174/0115734064318361240827072124
Raghav Mishra, Jayze da Cunha Xavier, Nitin Kumar, Gaurav Krishna, Prashant Kumar Dhakad, Helcio Silva Dos Santos, Paulo Nogueira Bandeira, Tigressa Helena Soares Rodrigues, Diego Romao Gondim, Walber Henrique Ferreira Ribeiro, Draulio Sales da Silva, Alexandre Magno Rodrigues Teixeira, Wandresa Francelino Pereira, Emmanuel Silva Marinho, Sucheta

Objectives: Malaria continues to be the primary cause of mortality worldwide, and timely recognition and prompt intervention are crucial in mitigating adverse consequences. This review article aims to examine the effectiveness and structural characteristics of quinoline-based compounds as antimalarial agents. It specifically focuses on their therapeutic effects as well as potential prospects for exploring structure-activity relationship (SAR). In addition, this study aims to identify lead compounds that can efficiently battle multidrug-resistant forms of Plasmodium falciparum and Plasmodium vivax.

Methods: A comprehensive review was conducted to evaluate the effectiveness of quinoline-based antimalarial medications in eradicating P. falciparum and P. vivax. The mechanism of action and SAR of these compounds were analyzed.

Results: Quinoline-based antimalarials demonstrated significant effectiveness in eliminating P. falciparum parasites, particularly in regions severely impacted by malaria, including Africa and Asia. These compounds were found to exhibit tolerance and immune-modulating properties, indicating their potential for more widespread utilization. The investigation identified various new quinoline compounds with improved antimalarial activity, including metal-chloroquine complexes, diaminealkyne chloroquines, and cinnamoylated chloroquine hybrids. This study explored different mechanisms by which these compounds interact with parasites, including their ability to accumulate in the parasite's acidic food vacuoles and disrupt heme detoxification. The derivatives demonstrated strong efficacy against chloroquine-resistant strains and yielded positive results.

Conclusion: Quinoline-based compounds represent a promising avenue for combating malaria due to their demonstrated efficacy against P. falciparum and P. vivax parasites. Further research on their mechanisms of action and SAR could lead to the development of more effective antimalarial medications.

目标:疟疾仍然是全世界死亡的主要原因,及时认识和迅速干预对减轻不良后果至关重要。本文综述了喹啉类抗疟药物的有效性和结构特点。特别着重于它们的治疗效果以及探索构效关系(SAR)的潜在前景。此外,本研究旨在鉴定能够有效对抗多重耐药形式的恶性疟原虫和间日疟原虫的先导化合物。方法:对喹诺林类抗疟药物在根除恶性疟原虫和间日疟原虫中的效果进行综合评价。分析了这些化合物的作用机理和合成孔径(SAR)。结果:以喹啉为基础的抗疟药物在消除恶性疟原虫方面显示出显著的有效性,特别是在疟疾严重影响的地区,包括非洲和亚洲。这些化合物被发现具有耐受性和免疫调节特性,表明它们具有更广泛应用的潜力。该研究发现了多种新的喹啉化合物,它们具有更好的抗疟活性,包括金属-氯喹配合物、二胺炔氯喹和肉桂化氯喹杂化物。这项研究探索了这些化合物与寄生虫相互作用的不同机制,包括它们在寄生虫的酸性食物液泡中积累和破坏血红素解毒的能力。该衍生物对氯喹耐药菌株具有较强的药效,并取得了阳性结果。结论:喹啉类化合物具有抗恶性疟原虫和间日疟原虫的功效,是一种很有前途的抗疟疾药物。对其作用机制和SAR的进一步研究将有助于开发更有效的抗疟药物。
{"title":"Exploring Quinoline Derivatives: Their Antimalarial Efficacy and Structural Features.","authors":"Raghav Mishra, Jayze da Cunha Xavier, Nitin Kumar, Gaurav Krishna, Prashant Kumar Dhakad, Helcio Silva Dos Santos, Paulo Nogueira Bandeira, Tigressa Helena Soares Rodrigues, Diego Romao Gondim, Walber Henrique Ferreira Ribeiro, Draulio Sales da Silva, Alexandre Magno Rodrigues Teixeira, Wandresa Francelino Pereira, Emmanuel Silva Marinho, Sucheta","doi":"10.2174/0115734064318361240827072124","DOIUrl":"10.2174/0115734064318361240827072124","url":null,"abstract":"<p><strong>Objectives: </strong>Malaria continues to be the primary cause of mortality worldwide, and timely recognition and prompt intervention are crucial in mitigating adverse consequences. This review article aims to examine the effectiveness and structural characteristics of quinoline-based compounds as antimalarial agents. It specifically focuses on their therapeutic effects as well as potential prospects for exploring structure-activity relationship (SAR). In addition, this study aims to identify lead compounds that can efficiently battle multidrug-resistant forms of <i>Plasmodium falciparum </i> and <i>Plasmodium vivax</i>.</p><p><strong>Methods: </strong>A comprehensive review was conducted to evaluate the effectiveness of quinoline-based antimalarial medications in eradicating <i>P. falciparum</i> and <i>P. vivax</i>. The mechanism of action and SAR of these compounds were analyzed.</p><p><strong>Results: </strong>Quinoline-based antimalarials demonstrated significant effectiveness in eliminating <i>P. falciparum</i> parasites, particularly in regions severely impacted by malaria, including Africa and Asia. These compounds were found to exhibit tolerance and immune-modulating properties, indicating their potential for more widespread utilization. The investigation identified various new quinoline compounds with improved antimalarial activity, including metal-chloroquine complexes, diaminealkyne chloroquines, and cinnamoylated chloroquine hybrids. This study explored different mechanisms by which these compounds interact with parasites, including their ability to accumulate in the parasite's acidic food vacuoles and disrupt heme detoxification. The derivatives demonstrated strong efficacy against chloroquine-resistant strains and yielded positive results.</p><p><strong>Conclusion: </strong>Quinoline-based compounds represent a promising avenue for combating malaria due to their demonstrated efficacy against <i>P. falciparum</i> and <i>P. vivax</i> parasites. Further research on their mechanisms of action and SAR could lead to the development of more effective antimalarial medications.</p>","PeriodicalId":18382,"journal":{"name":"Medicinal Chemistry","volume":"21 2","pages":"96-121"},"PeriodicalIF":1.9,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143502270","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Medicinal Chemistry
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1